Kloog Y - Search Results

1

Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats.

Goldberg L, Ocherashvilli A, Daniels D, Last D, Cohen ZR, Tamar G, Kloog Y, Mardor Y. Goldberg L, et al. Among authors: kloog y. Mol Cancer Ther. 2008 Nov;7(11):3609-16. doi: 10.1158/1535-7163.MCT-08-0488. Mol Cancer Ther. 2008. PMID: 19001442

2

E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition.

Blum R, Nakdimon I, Goldberg L, Elkon R, Shamir R, Rechavi G, Kloog Y. Blum R, et al. Among authors: kloog y. Int J Cancer. 2006 Aug 1;119(3):527-38. doi: 10.1002/ijc.21735. Int J Cancer. 2006. PMID: 16496386

3

A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration.

Goldberg L, Kloog Y. Goldberg L, et al. Among authors: kloog y. Cancer Res. 2006 Dec 15;66(24):11709-17. doi: 10.1158/0008-5472.CAN-06-1878. Cancer Res. 2006. PMID: 17178866

4

Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).

Zundelevich A, Elad-Sfadia G, Haklai R, Kloog Y. Zundelevich A, et al. Among authors: kloog y. Mol Cancer Ther. 2007 Jun;6(6):1765-73. doi: 10.1158/1535-7163.MCT-06-0706. Epub 2007 May 31. Mol Cancer Ther. 2007. PMID: 17541036

5

New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.

Goldberg L, Haklai R, Bauer V, Heiss A, Kloog Y. Goldberg L, et al. Among authors: kloog y. J Med Chem. 2009 Jan 8;52(1):197-205. doi: 10.1021/jm801165r. J Med Chem. 2009. PMID: 19072665

6

FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice.

Goldberg L, Israeli R, Kloog Y. Goldberg L, et al. Among authors: kloog y. Cell Death Dis. 2012 Mar 15;3(3):e284. doi: 10.1038/cddis.2012.24. Cell Death Dis. 2012. PMID: 22419113 Free PMC article.

7

Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).

Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y. Blum R, et al. Among authors: kloog y. Cancer Res. 2007 Apr 1;67(7):3320-8. doi: 10.1158/0008-5472.CAN-06-4287. Cancer Res. 2007. PMID: 17409441

8

The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.

Rotblat B, Ehrlich M, Haklai R, Kloog Y. Rotblat B, et al. Among authors: kloog y. Methods Enzymol. 2008;439:467-89. doi: 10.1016/S0076-6879(07)00432-6. Methods Enzymol. 2008. PMID: 18374183

9

Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.

Levy R, Grafi-Cohen M, Kraiem Z, Kloog Y. Levy R, et al. Among authors: kloog y. Mol Cancer Ther. 2010 Aug;9(8):2208-19. doi: 10.1158/1535-7163.MCT-10-0262. Epub 2010 Aug 3. Mol Cancer Ther. 2010. PMID: 20682656

10

Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.

Makovski V, Haklai R, Kloog Y. Makovski V, et al. Among authors: kloog y. Int J Cancer. 2012 Mar 15;130(6):1420-9. doi: 10.1002/ijc.26139. Epub 2011 Aug 1. Int J Cancer. 2012. PMID: 21500191

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

253 results

Search Page

Filters